1-7 of 7
Putting Into Practice: ctDNA Monitoring of ESR1 Mutations During 1L HR+/HER2− Advanced Breast Cancer
Innovations In MedicinePutting Into Practice: ctDNA Monitoring of ESR1 Mutations During 1L HR+/HER2− Advanced Breast Cancer
Earlier ESR1m Detection May Delay Endocrine Resistance in HR+/HER2- Advanced Breast Cancer
Innovations In MedicineEarlier ESR1m Detection May Delay Endocrine Resistance in HR+/HER2- Advanced Breast Cancer
Potential for Early Intervention in 1L HR+/HER2- Advanced Breast Cancer
Medical Industry FeaturePotential for Early Intervention in 1L HR+/HER2- Advanced Breast Cancer
Seth Wander, MD, PhD
ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer
Medical Industry FeatureReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Sarah Sammons, MD
Advancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
Medical Industry FeatureAdvancing Care in ER+/HER2− ESR1m mBC: What EMERALD and Real-World Analyses Tell Us
Jennifer Caudle, DO, FACOFP
Seth Wander, MD, PhD
Improving Preterm Birth Outcomes with Virtual Cervix Technology
Medical Industry FeatureImproving Preterm Birth Outcomes with Virtual Cervix Technology
Mirella Mourad, M.D.
- advertisement
Research Uncovers a Potential Biomarker for Postpartum Depression Risk
Medical Industry FeatureResearch Uncovers a Potential Biomarker for Postpartum Depression Risk
Lauren Osborne, M.D.
